Evidence map›Paper›PMID 33282308›Full record

ArticleSAGE open medicine2020

Cystathionine β-synthase and methylenetetrahydrofolate reductase mutations in Mexican individuals with hyperhomocysteinemia.

Anahi Guadalupe Figueroa-Torres, Lisneth Osiris Matias-Aguilar, Erika Coria-Ramirez, Edmundo Bonilla-Gonzalez, Humberto Gonzalez-Marquez, Isabel Ibarra-Gonzalez, Jose Rubicel Hernandez-Lopez, Jesus Hernandez-Juarez, Victor Manuel Dominguez-Reyes, Irma Isordia-Salas and 1 more

Open access · goldAbstract read
In one paragraph

Article in SAGE open medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 77% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Anahi Guadalupe Figueroa-TorresUnidad de Investigación Médica en Trombosis, Hemostasia y Aterogénesis, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico.
Lisneth Osiris Matias-AguilarUnidad de Investigación Médica en Trombosis, Hemostasia y Aterogénesis, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico.
Erika Coria-RamirezUnidad de Investigación Médica en Trombosis, Hemostasia y Aterogénesis, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico.
Edmundo Bonilla-GonzalezDepartamento de Ciencias de la Salud, Universidad Autónoma Metropolitana, Ciudad de México, México.
Humberto Gonzalez-MarquezDepartamento de Ciencias de la Salud, Universidad Autónoma Metropolitana, Ciudad de México, México.
Isabel Ibarra-GonzalezUnidad de Genética de la Nutrición, Instituto de Investigaciones Biomédica UNAM-Instituto Nacional de Pediatría, Secretaría de Salud, Ciudad de México, México.
Jose Rubicel Hernandez-LopezUnidad de Investigación Médica en Trombosis, Hemostasia y Aterogénesis, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico.
Jesus Hernandez-JuarezUnidad de Investigación Médica en Trombosis, Hemostasia y Aterogénesis, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico.
Victor Manuel Dominguez-ReyesUnidad de Investigación Médica en Trombosis, Hemostasia y Aterogénesis, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico.
Irma Isordia-SalasUnidad de Investigación Médica en Trombosis, Hemostasia y Aterogénesis, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico.
Abraham Majluf-CruzUnidad de Investigación Médica en Trombosis, Hemostasia y Aterogénesis, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico.ORCID https://orcid.org/0000-0002-7697-5790
Mexican Social Security Institute · MXUniversidad Autónoma Metropolitana · MXInstituto Nacional de Pediatria · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyperhomocysteinemia, a thrombotic risk factor, may have several causes. Among the genetic causes of hyperhomocysteinemia, there are polymorphisms in the enzymes methylenetetrahydrofolate reductase (C677T) and cystathionine β-synthase (C699T, C1080T, and 844ins68). Although the frequency of hyperhomocysteinemia in our country is high, there is no evidence about the frequencies of these polymorphisms.

methodsWe analyzed 80 healthy individuals from several regions in our country. We evaluated the fasting and post-oral methionine load plasma Hcy and the genotypes in order to obtain the allele frequencies of the polymorphisms C677T of methylenetetrahydrofolate reductase and C699T, C1080T, and 844ins68 of the cystathionine β-synthase.

resultsNo individual had deficiency of folic acid, vitamins B12, or B6, but 80% had post-oral methionine load hyperhomocysteinemia. We found a significant increase in the Hcy plasma concentration associated with age and gender. Only the polymorphism C1080T was significantly associated with hyperhomocysteinemia.

conclusionThere is an association between fasting and post-oral methionine load plasma Hcy concentrations with the allelic frequencies of the polymorphisms C669T, 844ins68, and C1080T of the cystathionine β-synthase and C667T of the methylenetetrahydrofolate reductase in healthy Mexican individuals. As compared with individuals with normal fasting or post-oral methionine load Hcy plasma levels, only C1080T was significantly associated with hyperhomocysteinemia.

Indexed as

cystathionine beta-synthaseHomocysteinehyperhomocysteinemethylenetetrahydrofolate reductaseoral methionine load

Identifiers

PMID33282308
PMCPMC7682208
OpenAlexW3106638086

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.